Swing,from the Feb. 11,2013 earnings call:

Operator

[Operator Instructions] Our next question is from Simos Simeonidis with Cowen and Company.

Simos Simeonidis - Cowen and Company, LLC, Research Division

A question for Bob. I know you're blinded on the data. But your data monitoring committee, have they seen any concerns of hypoglycemias up to this point?

Robert Baughman

I can tell you that the data is being reviewed, and we have not been alerted to any concern with hypos in the studies.

Simos Simeonidis - Cowen and Company, LLC, Research Division

Okay, great. And the final question for Matt. Matt, how much is available under the line of credit from Al?

Matthew J. Pfeffer - Chief Financial Officer, Principal Accounting Officer and Corporate Vice President

Approximately $120 million.

Simos Simeonidis - Cowen and Company, LLC, Research Division

As of the start of the quarter, right? Or I guess the end of the quarter, I should say.

Matthew J. Pfeffer - Chief Financial Officer, Principal Accounting Officer and Corporate Vice President

I mean, obviously, we haven't drawn anything from that since the financing. So the full amount remains available. Remember, when Al bought the stock he reinstated that portion of the debt back into the line should we need it. Obviously, we hope we won't.

http://seekingalpha.com/article/1173611-mannkind-management-discusses-q4-2012-results-earnings-call-transcript?find=trials&all=false